Drug Approval | April 24, 2023
USFDA suggests corrective measures to Sun Pharmaceutical’s Mohali facility
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
Aji Bio-Pharma has six fill finish lines located in San Diego, including a new line
The acquisition would be by way of a share purchase agreement dated Dec. 26, 2022.
With a focus on optimizing patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette’s existing pharma innovation centers in France and Singapore
SÜDPACK is setting standards in terms of both performance and sustainability
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
Study efficacy measures will include the expression of dystrophin protein and motor function.
Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases.
Subscribe To Our Newsletter & Stay Updated
